Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases
Deadline for Applications is November 12 th , 2021
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fourth annual Cytokinetics Communications Fellowship Grant program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure, hypertrophic cardiomyopathy (HCM), or spinal muscular atrophy (SMA) communities, and is intended to support increased capacity in communications and outreach.
"We are proud to continue our Communications Fellowship Grant program in the coming year as further evidence of our commitment to the patient communities we serve," said Mary Pomerantz, Cytokinetics' Director of Advocacy. "Through these grants we hope to help address gaps in awareness and outreach as can be enabling patient advocacy organizations to elevate patient and caregiver voices as well as to engage new audiences."
The goal of the Cytokinetics Communications Fellowship Grant program is to assist patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Fellowship Grant program supports programming or personnel, depending on each organization's needs. The recipients of the 2021 Cytokinetics Communications Fellowship Grants were The ALS Association Oregon and SW Washington Chapter, The ALS Association Massachusetts Chapter, Camp Taylor, Partnership to Advance Cardiovascular Health, and WomenHeart: The National Coalition for Women with Heart Disease.
Eligible organizations must have nonprofit organization status in the United States and serve the cardiovascular or neuromuscular patient communities in ALS, heart failure, HCM or SMA. The deadline to apply is November 12, 2021 and the grant recipients will be announced in January 2022.
Organizations applying for the grant are required to submit a proposal outlining what activities the Cytokinetics Communications Fellowship Grant program will support and the potential impact of the funding. Recipients are responsible for providing an outcomes report to Cytokinetics to measure impact at the end of the funding period. For more information on application criteria, and instructions for how to apply, visit www.cytokinetics.com/fellowship. About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing a U.S. NDA submission of omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). The company has announced positive results from Cohorts 1 and 2 in REDWOOD-HCM, a Phase 2 clinical trial of aficamten in patients with obstructive HCM. Cytokinetics expects to start a Phase 3 clinical trial of aficamten in patients with obstructive HCM in Q4 2021. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlines in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:Diane WeiserSenior Vice President, Corporate Communications, Investor Relations(415) 290-7757